Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Sell
45
MREO Quote, Financials, Valuation and Earnings
Last price:
$2.14
Seasonality move
:
63%
Day range:
$2.11 - $2.22
52-week range:
$1.58 - $5.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.69x
Volume:
658.3K
Avg. volume:
1.3M
1-year change:
-40.11%
Market cap:
$341.9M
Revenue:
$10M
EPS (TTM):
-$0.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$15.9M | -$0.01 | -100% | -87.66% | $7.59 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -91.39% | -8.33% | $1.58 |
|
AUTL
Autolus Therapeutics PLC
|
$2M | -$0.25 | -80.39% | -10.73% | $9.97 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$54.8M | -$0.03 | -- | -99.24% | $94.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$2.15 | $7.59 | $341.9M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.29 | $1.58 | $77.5M | -- | $0.00 | 0% | 0.42x |
|
AUTL
Autolus Therapeutics PLC
|
$1.75 | $9.97 | $465.7M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.08 | $17.94 | $3.1M | -- | $0.00 | 0% | 1.12x |
|
NCNA
NuCana PLC
|
$0.04 | $104.00 | $213.8K | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$81.20 | $94.10 | $6.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.393 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.631 | 50.03% | 1.57x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 1.803 | -- | 8.74x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.357 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | -0.390 | -- | -- |
|
VRNA
Verona Pharma PLC
|
51.62% | 0.242 | 4.47% | 8.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$11M | -- | -- | -- | -$8.6M |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$72.8M | -$10.3M | -51.07% | -85.84% | -8.34% | -$12.1M |
Mereo BioPharma Group PLC vs. Competitors
-
Which has Higher Returns MREO or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -653.18%. Mereo BioPharma Group PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M -
What do Analysts Say About MREO or ADAP?
Mereo BioPharma Group PLC has a consensus price target of $7.59, signalling upside risk potential of 253.16%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 438.89%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 ADAPAdaptimmune Therapeutics PLC3 3 0 -
Is MREO or ADAP More Risky?
Mereo BioPharma Group PLC has a beta of 0.465, which suggesting that the stock is 53.542% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.
-
Which is a Better Dividend Stock MREO or ADAP?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or ADAP?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Mereo BioPharma Group PLC's net income of -$12.9M is higher than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 0.42x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M ADAPAdaptimmune Therapeutics PLC0.42x -- $7.3M -$47.6M
-
Which has Higher Returns MREO or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -781.13%. Mereo BioPharma Group PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About MREO or AUTL?
Mereo BioPharma Group PLC has a consensus price target of $7.59, signalling upside risk potential of 253.16%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.97 which suggests that it could grow by 469.52%. Given that Autolus Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Autolus Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 AUTLAutolus Therapeutics PLC7 0 0 -
Is MREO or AUTL More Risky?
Mereo BioPharma Group PLC has a beta of 0.465, which suggesting that the stock is 53.542% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.723%.
-
Which is a Better Dividend Stock MREO or AUTL?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or AUTL?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $9M. Mereo BioPharma Group PLC's net income of -$12.9M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns MREO or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About MREO or BDRX?
Mereo BioPharma Group PLC has a consensus price target of $7.59, signalling upside risk potential of 253.16%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1561.47%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is MREO or BDRX More Risky?
Mereo BioPharma Group PLC has a beta of 0.465, which suggesting that the stock is 53.542% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.
-
Which is a Better Dividend Stock MREO or BDRX?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BDRX?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$12.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 1.12x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M BDRXBiodexa Pharmaceuticals PLC1.12x -- -- --
-
Which has Higher Returns MREO or NCNA?
NuCana PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About MREO or NCNA?
Mereo BioPharma Group PLC has a consensus price target of $7.59, signalling upside risk potential of 253.16%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 294517.56%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 NCNANuCana PLC0 1 0 -
Is MREO or NCNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.465, which suggesting that the stock is 53.542% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.
-
Which is a Better Dividend Stock MREO or NCNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or NCNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$12.9M is lower than NuCana PLC's net income of -$836.1K. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns MREO or VRNA?
Verona Pharma PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -21.4%. Mereo BioPharma Group PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -85.84%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- VRNAVerona Pharma PLC95.53% -$0.16 $468.3M -
What do Analysts Say About MREO or VRNA?
Mereo BioPharma Group PLC has a consensus price target of $7.59, signalling upside risk potential of 253.16%. On the other hand Verona Pharma PLC has an analysts' consensus of $94.10 which suggests that it could grow by 15.89%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 VRNAVerona Pharma PLC7 0 0 -
Is MREO or VRNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.465, which suggesting that the stock is 53.542% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.206, suggesting its less volatile than the S&P 500 by 79.434%.
-
Which is a Better Dividend Stock MREO or VRNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or VRNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. Mereo BioPharma Group PLC's net income of -$12.9M is higher than Verona Pharma PLC's net income of -$16.3M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M VRNAVerona Pharma PLC-- -- $76.3M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
